verified SJR 11,319 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Elsevier Ltd

workspace_premium Q1 — Oncology visibility_off Single blind Peer Review lock_open Open Access Unclaimed

The Lancet Oncology

The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 432. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer,. It has an SJR impact factor of 11,319 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 11,319.

The Lancet Oncology focuses its scope in these topics and keywords: cancer, phase, patients, randomised, metastatic, care, advanced, openlabel, multicentre, doubleblind, ...

ISSN: 1470-2045

Editorial: Elsevier Ltd

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Visitar Portal de la Editorial menu_book Guía para Autores (Guidelines)

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

11,319 Q1

H-index 432

Tasa de Aceptación pie_chart

16% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

2.395 € Open Access

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

11,319

H-index

432

Docs (year)

475

Docs 3y

1353

Total refs

7356

Cites 3y

15163

Citable 3y

636

Cites/Doc 2y

9.61

Ref/Doc

15.49

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Australian scientists design novel antiangiogenic weapon

Why do hypoxic cells behave badly?

Chlorophyllin reduces risk of aflatoxin-induced liver cancer

Chemotherapy and anaesthetic drugs: too little is known

Chemoprevention: eat ginger, rub on pomegranate

CCI-779: a new targeted anticancer agent

Cancer sites for children are few and far between

Cancer Institute at Chennai: a model for resource-poor countries

Cancer and ethnic minorities

Canadian researchers uncover vital new clues in cancer

Bring back the acetyls - a novel anticancer movement

Breast reconstruction cannot exorcise phantom pain

SHOW MORE ARTICLES

Breast cancer in women after treatment for Hodgkin's disease

A new approach to managing prostate cancer is essential

Australian cancer survival figures greatly improved

Australia approves thalidomide

Association of the British Pharmaceutical Industry says...

An extra defence against skin cancer?

Amgen's point of view on epoetins

Alternative medicine and cancer patients in less developed countries

Alternative cancer cures

Allan van Oosterom, President of the EORTC

Alan Coates -CEO of the Australian Cancer Society

Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.